Joseph Gibbons

621 total citations
17 papers, 491 citations indexed

About

Joseph Gibbons is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Joseph Gibbons has authored 17 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Hematology. Recurrent topics in Joseph Gibbons's work include Cancer Treatment and Pharmacology (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Genomics and Diagnostics (4 papers). Joseph Gibbons is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Genomics and Diagnostics (4 papers). Joseph Gibbons collaborates with scholars based in United States. Joseph Gibbons's co-authors include Paul W. Sperduto, Bruce J. Gerbi, Walter A. Hall, Hamid R. Djalilian, H. Brent Clark, Scot C. Remick, Afshin Dowlati, Pingfu Fu, Smitha Krishnamurthi and Joseph A. Bokar and has published in prestigious journals such as Journal of Clinical Oncology, The Oncologist and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Joseph Gibbons

15 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph Gibbons United States 10 193 180 173 102 100 17 491
Tahir Latif United States 13 214 1.1× 108 0.6× 91 0.5× 211 2.1× 74 0.7× 38 588
Akiko Chai United States 14 193 1.0× 118 0.7× 176 1.0× 129 1.3× 127 1.3× 21 710
Michael H. Brave United States 9 374 1.9× 158 0.9× 126 0.7× 136 1.3× 35 0.3× 15 664
Lawrence Garbo United States 15 427 2.2× 188 1.0× 69 0.4× 311 3.0× 109 1.1× 35 741
Yanzhi Hsu United States 16 340 1.8× 429 2.4× 76 0.4× 108 1.1× 73 0.7× 42 891
Sasja F. Mulder Netherlands 12 253 1.3× 340 1.9× 70 0.4× 265 2.6× 54 0.5× 38 669
Kenichi Harano Japan 14 401 2.1× 131 0.7× 54 0.3× 115 1.1× 44 0.4× 70 702
Brendan Rooney United Kingdom 10 244 1.3× 295 1.6× 141 0.8× 111 1.1× 19 0.2× 21 593
M.S. Gordon United States 14 212 1.1× 219 1.2× 115 0.7× 309 3.0× 24 0.2× 89 686
A. McDonald United Kingdom 14 409 2.1× 203 1.1× 57 0.3× 210 2.1× 52 0.5× 19 721

Countries citing papers authored by Joseph Gibbons

Since Specialization
Citations

This map shows the geographic impact of Joseph Gibbons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Gibbons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Gibbons more than expected).

Fields of papers citing papers by Joseph Gibbons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Gibbons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Gibbons. The network helps show where Joseph Gibbons may publish in the future.

Co-authorship network of co-authors of Joseph Gibbons

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Gibbons. A scholar is included among the top collaborators of Joseph Gibbons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Gibbons. Joseph Gibbons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Eads, Jennifer R., Smitha Krishnamurthi, Joel Saltzman, et al.. (2020). Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. Investigational New Drugs. 39(1). 142–151. 10 indexed citations
2.
Eads, Jennifer R., Smitha Krishnamurthi, Joel Saltzman, et al.. (2015). Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 2558–2558. 2 indexed citations
3.
Chee, Cheng Ean, Smitha Krishnamurthi, Charles Nock, et al.. (2013). Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas. The Oncologist. 18(10). 1091–1092. 61 indexed citations
4.
Cooney, Matthew M., Charles Nock, Joseph A. Bokar, et al.. (2012). Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(5). 755–761. 7 indexed citations
5.
Brell, Joanna M., Smitha Krishnamurthi, Linda Rath, et al.. (2012). Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(4). 547–553. 10 indexed citations
6.
Nock, Charles, Joanna M. Brell, Joseph A. Bokar, et al.. (2009). A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investigational New Drugs. 29(1). 126–130. 17 indexed citations
7.
Gibbons, Joseph, et al.. (2009). Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy. World Journal of Surgical Oncology. 7(1). 30–30. 8 indexed citations
8.
9.
Gibbons, Joseph, Merrill J. Egorin, Ramesh K. Ramanathan, et al.. (2008). Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology. 26(4). 570–576. 106 indexed citations
10.
Gibbons, Joseph, Smitha Krishnamurthi, Joanna M. Brell, et al.. (2008). Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Investigational New Drugs. 27(5). 453–460. 18 indexed citations
11.
Dowlati, Afshin, et al.. (2008). Multi-Institutional Phase I Trials of Anticancer Agents. Journal of Clinical Oncology. 26(12). 1926–1931. 18 indexed citations
12.
Cooney, Matthew M., Afshin Dowlati, Joanna M. Brell, et al.. (2008). Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Investigational New Drugs. 26(4). 355–362. 16 indexed citations
13.
Krishnamurthi, Smitha, Joanna M. Brell, Charles L. Hoppel, et al.. (2008). Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemotherapy and Pharmacology. 63(3). 441–450. 9 indexed citations
14.
Singh, Deepti, Linda Rath, Joseph A. Bokar, et al.. (2008). Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 26(15_suppl). 15076–15076.
15.
Dowlati, Afshin, et al.. (2007). Multi-institutional phase I trials involve more patients and longer accrual time compared to single institution trials. Journal of Clinical Oncology. 25(18_suppl). 2500–2500.
16.
Cooney, Matthew M., Joseph Gibbons, Joanna M. Brell, et al.. (2007). Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3570–3570. 2 indexed citations
17.
Hall, Walter A., Hamid R. Djalilian, Paul W. Sperduto, et al.. (1995). Stereotactic radiosurgery for recurrent malignant gliomas.. Journal of Clinical Oncology. 13(7). 1642–1648. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tahir Latif Breakdown of academic impact, for papers by Akiko Chai Breakdown of academic impact, for papers by Michael H. Brave Breakdown of academic impact, for papers by Lawrence Garbo Breakdown of academic impact, for papers by Yanzhi Hsu Breakdown of academic impact, for papers by Sasja F. Mulder Breakdown of academic impact, for papers by Kenichi Harano Breakdown of academic impact, for papers by Brendan Rooney Breakdown of academic impact, for papers by M.S. Gordon Breakdown of academic impact, for papers by A. McDonald
Rankless by CCL
2026